Ann: Trading Halt, page-34

Hmmm yes Vogelworld, the need for what our drug does is certainly magnified under these conditions. Elective surgeries have gone on to the back burner as you say (in Aus and US and prob so many other countries) and yes the FDA would be aware that a drug such as our could be a real God-send...BUT I personally feel that though we know we may be in a better position to attract a designation such as Fast Track/Priority and perhaps later Break Through, we will still need to traverse down the path of the usual trial corridors though it might be somewhat accelerated (Fingers crossed)...there is a small chance we could get these designations early but I would've thought the FDA would need more time viewing our data before declaring this? (Hence my speculation of this occurring more toward Q3/Q4? )

As you suggest there is a chance the FDA also may declare a similar statement to what we heard from Paul...it would be good news to hear this officially in the soon to be published minutes.